ライフサイエンスコーパス: uterine leiomyoma

1 gning nonsurgical therapeutic strategies for uterine leiomyoma.

2 ly deleted in malignant myeloid diseases and uterine leiomyoma.

3 ranscriptional dysregulation in MED12 mutant uterine leiomyomas.

4 ED12-LM) and HMGA2-overexpressing (HMGA2-LM) uterine leiomyomas.

5 mangiomas, liver cysts, thyroid nodules, and uterine leiomyomas.

6 re exploration of novel target therapies for uterine leiomyomas.

7 n and progesterone, leading to the growth of uterine leiomyomas.

8 of women with cutaneous leiomyomas also had uterine leiomyomas.

9 in a syndrome called multiple cutaneous and uterine leiomyomas.

10 extended family with multiple cutaneous and uterine leiomyomas.

11 18, suggesting a pathogenesis in common with uterine leiomyomas.

12 onance (MR) evaluation of known or suspected uterine leiomyomas.

13 n extremely common hormone-responsive tumor, uterine leiomyoma, a tumor with a significant impact on

14 mimic the effects of endogenous estrogens on uterine leiomyoma and may contribute to a complex hormon

15 NA-binding activity in protein extracts from uterine leiomyoma and normal myometrium tissues.

16 sor gene in the development of cutaneous and uterine leiomyoma and renal cell cancer in this syndrome

17 h HLRCC are at risk to develop cutaneous and uterine leiomyomas and an aggressive form of kidney canc

18 q22, in the minimal region deleted in 10% of uterine leiomyomas and in 10-20% of acute myeloid leukem

19 und causes thermocoagulation and necrosis in uterine leiomyomas and is feasible and safe, without ser

20 succinate dehydrogenase have been linked to uterine leiomyomas and paragangliomas, and cancer cells

21 cterized by the development of cutaneous and uterine leiomyomas and risk for development of an aggres

22 the genetic locus for multiple cutaneous and uterine leiomyomas and the availability of an extended m

23 quencing and gene-expression profiling of 38 uterine leiomyomas and the corresponding myometrium from

24 duce a new, noninvasive treatment method for uterine leiomyomas and to present a comparison with othe

25 tiated mesenchymal tumors including lipomas, uterine leiomyomas, and pulmonary chondroid hamartomas.

26 Found in as many as 80% of women, uterine leiomyomas are a frequent cause of abnormal uter

27 Uterine leiomyomas are benign but affect the health of m

28 Uterine leiomyomas are benign tumors that can cause pain

29 Uterine leiomyomas are common benign smooth muscle tumor

30 Uterine leiomyomas are extremely common estrogen and pro

31 Multiple cutaneous and uterine leiomyomas are inherited as an autosomal dominan

32 Uterine leiomyomas are reported to be the most common be

33 s were shown to cause multiple cutaneous and uterine leiomyomas as well as hereditary leiomyomatosis

34 The authors investigated the risk of uterine leiomyoma associated with exposure to 2,3,7,8,-t

35 that of previously reported MED12 lesions in uterine leiomyoma but not those of other tumors.

36 d focused ultrasound surgery in treatment of uterine leiomyomas by using two treatment protocols.

37 progesterone stimulates the proliferation of uterine leiomyoma cells, the mechanism of progesterone a

38 ors could be seeded from a single lineage of uterine leiomyoma cells.

39 egrator of PR signaling and proliferation in uterine leiomyoma cells.

40 sc2-/- mouse embryonic fibroblasts, Eker rat uterine leiomyoma-derived Tsc2-deficient ELT3 cells, mut

41 e principal DEHP metabolite, and the risk of uterine leiomyoma diagnosis (n = 712 patients).

42 men with a previous or coincident history of uterine leiomyoma, especially when no evidence of other

43 rospective trial performed in the context of uterine leiomyoma evaluation.

44 this study was to determine if benign human uterine leiomyoma (fibroid) cells could be malignantly t

45 Uterine leiomyomas (fibroids or myomas), benign tumours

46 Uterine leiomyomas (fibroids) are a major source of gyne

47 of women of reproductive age are affected by uterine leiomyomas (fibroids).

48 nstrated that this alteration alone promotes uterine leiomyoma formation and hyperplasia in both WT m

49 the genetic locus for multiple cutaneous and uterine leiomyomas, from 14 cM to an interval of 4.55 or

50 percent (41/46) of women with cutaneous and uterine leiomyomas had a total hysterectomy, 44% at age

51 (MED12) exon 2 variants are associated with uterine leiomyomas; however, the causality of MED12 vari

52 on uterine fibrosis, we developed a 3D human uterine leiomyoma (ht-UtLM) spheroid culture model.

53 diodes on monosodium glutamate (MSG)-induced uterine leiomyoma in albino rats and proposed their mech

54 Uterine leiomyoma is an estrogen-responsive tumor, and t

55 ulator (SERM) for the potential treatment of uterine leiomyoma is described.

56 Uterine leiomyoma is the most common benign tumor in rep

57 Uterine leiomyoma is the most common tumor in women and

58 Uterine leiomyoma is the most common tumor of the female

59 maging-guided focused ultrasound surgery for uterine leiomyomas is reported.

60 Myomectomy, the excision of uterine leiomyoma, is now commonly performed via minimal

61 genomic studies have identified subtypes of uterine leiomyoma (LM) with distinctive genetic alterati

62 rone and its receptor, PR, are essential for uterine leiomyoma (LM, a.k.a., fibroid) tumorigenesis, b

63 Uterine leiomyomas or fibroids (UFs) are benign tumors c

64 actor for nine non-ASCVD diseases, including uterine leiomyoma (OR 1.19, 95% CI 1.10-1.29, p=1.17 x 1

65 Uterine leiomyomas (or fibroids) are the most common tum

66 These results suggest that in uterine leiomyomas PPARgamma activation is growth inhibi

67 inizing hormone (LH) levels, the MSG-induced uterine leiomyoma rats also had noticeably higher levels

68 terone receptor (PR) target genes in primary uterine leiomyoma smooth muscle cells.

69 This report describes a uterine leiomyoma specimen with an inv(6)(p21q15).

70 fects of estradiol and progesterone on these uterine leiomyoma subtypes emphasize the importance of s

71 al characteristics of the two most prevalent uterine leiomyoma subtypes, MED12-mutant (MED12-LM) and

72 aft assay was driven by progesterone in both uterine leiomyoma subtypes.

73 ne (FH) predispose to multiple cutaneous and uterine leiomyoma syndrome (MCL) and MCL associated with

74 nd define novel proteogenomic alterations in uterine leiomyoma tissues collected from HLRCC patients

75 ying the phenotypic association observed for uterine leiomyoma (UL) and breast cancer (BC).

76 In vitro studies have shown that uterine leiomyoma (UL) cells proliferate in response to

77 mmonly seen in benign smooth muscle tumor as uterine leiomyoma (UL).

78 Uterine leiomyomas (UL) are benign tumors that arise in

79 (HLRCC) and increase the risk of developing uterine leiomyomas (ULMs).

80 studied disease associations (hypertension, uterine leiomyoma, vitamin D deficiency, atopic eczema)

81 The association with uterine leiomyoma was borderline significant in Black wo

82 (Tsc-2) tumor-suppressor gene predisposed to uterine leiomyomas, we show that an early-life exposure

83 major cause of chromosomal abnormalities in uterine leiomyomas; we propose that tumorigenesis occurs

84 Approximately 90% of cells in HMGA2-uterine leiomyoma were smooth muscle cells (SMC) with HM

85 to matched specimens of healthy myometrium, uterine leiomyomas were characterized by reduced CD73 ex

86 gene responsible for multiple cutaneous and uterine leiomyomas, which, in turn, may provide key info

87 ted genetic locus for multiple cutaneous and uterine leiomyomas, with a maximum two-point LOD score o